Literature DB >> 32783068

Emerging roles of microRNAs and their implications in uveal melanoma.

Chun Yang1, Yuejiao Wang2, Pierre Hardy3,4.   

Abstract

Uveal melanoma (UM) is the most common intraocular malignant tumor in adults with an extremely high mortality rate. Genetic and epigenetic dysregulation contribute to the development of UM. Recent discoveries have revealed dysregulation of the expression levels of microRNAs (miRNAs) as one of the epigenetic mechanisms underlying UM tumorigenesis. Based on their roles, miRNAs are characterized as either oncogenic or tumor suppressive. This review focuses on the roles of miRNAs in UM tumorigenesis, diagnosis, and prognosis, as well as their therapeutic potentials. Particularly, the actions of collective miRNAs are summarized with respect to their involvement in major, aberrant signaling pathways that are implicated in the development and progression of UM. Elucidation of the underlying functional mechanisms and biological aspects of miRNA dysregulation in UM is invaluable in the development of miRNA-based therapeutics, which may be used in combination with conventional treatments to improve therapeutic outcomes. In addition, the expression levels of some miRNAs are correlated with UM initiation and progression and, therefore, may be used as biomarkers for diagnosis and prognosis.

Entities:  

Keywords:  Biomarkers; Ocular melanoma; Signaling pathway; Therapeutic; microRNAs

Year:  2020        PMID: 32783068     DOI: 10.1007/s00018-020-03612-w

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  122 in total

Review 1.  Clinical, Histopathological and Cytogenetic Prognosticators in Uveal Melanoma - A Comprehensive Review.

Authors:  Tomasz Berus; Agnieszka Halon; Anna Markiewicz; Jolanta Orlowska-Heitzman; Bozena Romanowska-Dixon; Piotr Donizy
Journal:  Anticancer Res       Date:  2017-12       Impact factor: 2.480

2.  Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26.

Authors:  Marie Diener-West; Sandra M Reynolds; Donna J Agugliaro; Robert Caldwell; Kristi Cumming; John D Earle; Barbara S Hawkins; James A Hayman; Ishmael Jaiyesimi; Lee M Jampol; John M Kirkwood; Wui-Jin Koh; Dennis M Robertson; John M Shaw; Bradley R Straatsma; Jonni Thoma
Journal:  Arch Ophthalmol       Date:  2005-12

3.  Meta-analysis on the utility of radiotherapy for the treatment of Ocular Melanoma

Authors:  D Messineo; G Barile; S Morrone; G La Torre; P Turchetti; L Accetta; E Trovato Battagliola; E Agostinelli; F Pacella
Journal:  Clin Ter       Date:  2020 Jan-Feb

4.  Genetics of uveal melanoma and cutaneous melanoma: two of a kind?

Authors:  Thomas van den Bosch; Emine Kilic; Dion Paridaens; Annelies de Klein
Journal:  Dermatol Res Pract       Date:  2010-06-06

5.  Identification of monosomy 3 in choroidal melanoma by chromosome in situ hybridisation.

Authors:  M T Sandinha; M A Farquharson; F Roberts
Journal:  Br J Ophthalmol       Date:  2004-12       Impact factor: 4.638

Review 6.  Focus on cutaneous and uveal melanoma specificities.

Authors:  Charlotte Pandiani; Guillaume E Béranger; Justine Leclerc; Robert Ballotti; Corine Bertolotto
Journal:  Genes Dev       Date:  2017-04-15       Impact factor: 11.361

7.  A Panel of Circulating MicroRNAs Detects Uveal Melanoma With High Precision.

Authors:  Mitchell S Stark; Elin S Gray; Timothy Isaacs; Fred K Chen; Michael Millward; Ashleigh McEvoy; Pauline Zaenker; Melanie Ziman; H Peter Soyer; William J Glasson; Sunil K Warrier; Andrew L Stark; Olivia J Rolfe; Jane M Palmer; Nicholas K Hayward
Journal:  Transl Vis Sci Technol       Date:  2019-11-14       Impact factor: 3.283

8.  Distribution of GNAQ and GNA11 Mutation Signatures in Uveal Melanoma Points to a Light Dependent Mutation Mechanism.

Authors:  Mark J de Lange; Lubna Razzaq; Mieke Versluis; Sven Verlinde; Mehmet Dogrusöz; Stefan Böhringer; Marina Marinkovic; Gregorius P M Luyten; Rob J W de Keizer; Frank R de Gruijl; Martine J Jager; Pieter A van der Velden
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

9.  Digital PCR validates 8q dosage as prognostic tool in uveal melanoma.

Authors:  Mieke Versluis; Mark J de Lange; Sake I van Pelt; Claudia A L Ruivenkamp; Wilma G M Kroes; Jinfeng Cao; Martine J Jager; Gre P M Luyten; Pieter A van der Velden
Journal:  PLoS One       Date:  2015-03-12       Impact factor: 3.240

Review 10.  Immunobiology of Uveal Melanoma: State of the Art and Therapeutic Targets.

Authors:  Maria Sofia Basile; Emanuela Mazzon; Paolo Fagone; Antonio Longo; Andrea Russo; Matteo Fallico; Vincenza Bonfiglio; Ferdinando Nicoletti; Teresio Avitabile; Michele Reibaldi
Journal:  Front Oncol       Date:  2019-11-05       Impact factor: 6.244

View more
  4 in total

Review 1.  Prognostic Biomarkers in Uveal Melanoma: The Status Quo, Recent Advances and Future Directions.

Authors:  Nuno Jorge Lamas; Arnaud Martel; Sacha Nahon-Estève; Samantha Goffinet; Adam Macocco; Corine Bertolotto; Sandra Lassalle; Paul Hofman
Journal:  Cancers (Basel)       Date:  2021-12-25       Impact factor: 6.639

Review 2.  Genetic Basis and Molecular Mechanisms of Uveal Melanoma Metastasis: A Focus on Prognosis.

Authors:  Carla Enrica Gallenga; Elena Franco; Ginevra Giovanna Adamo; Sara Silvia Violanti; Paolo Tassinari; Mauro Tognon; Paolo Perri
Journal:  Front Oncol       Date:  2022-04-11       Impact factor: 5.738

3.  Proteomics analysis: inhibiting the expression of P62 protein by chloroquine combined with dacarbazine can reduce the malignant progression of uveal melanoma.

Authors:  Xifeng Fei; Xiangtong Xie; Ruwei Qin; Anqi Wang; Xuan Meng; Fei Sun; Yifan Zhao; Dongyi Jiang; Hanchun Chen; Qiang Huang; Xiaoyan Ji; Zhimin Wang
Journal:  BMC Cancer       Date:  2022-04-14       Impact factor: 4.430

4.  MiR-31 improves spinal cord injury in mice by promoting the migration of bone marrow mesenchymal stem cells.

Authors:  Yujuan Zhang; Lili Cao; Ruochen Du; Feng Tian; Xiao Li; Yitong Yuan; Chunfang Wang
Journal:  PLoS One       Date:  2022-09-06       Impact factor: 3.752

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.